Delta 9 Receives Renewal of Health Canada License and Oils Sales Authorization

Delta 9公司获得加拿大卫生部大麻许可证三年续期

2019-09-05 08:34:50 CFN Media Group

本文共1459个字,阅读需4分钟

DELTA 9 CANNABIS INC. , is pleased to announce that on August 30, 2019 it received its renewal license from Health Canada for a term of three years. This license authorizes Delta 9 to cultivate, process and sell cannabis from its Winnipeg production facility. The Company is also pleased to provide investors with an update on cannabis oils sales, cannabis pre-rolls sales, and new product development. Health Canada License Renewal and Oils Sales Authorization The Company, through its subsidiary, Delta 9 Bio-Tech Inc., has received its renewed Standard Cultivation and Standard Processing license for cannabis from Health Canada. The Company has fulfilled Health Canada’s rigorous specifications, and successfully passed all inspections. “Delta 9 employees have worked hard to meet the requirements within Health Canada’s strictly regulated licensing environment. It speaks to the professionalism of our team that it has maintained the high standards of safety, quality and security in accordance with Health Canada’s regulations for licensed producers,” said John Arbuthnot, Chief Executive Officer of Delta 9. The Company has also received approval from Health Canada for sales of cannabis oil products. The Company has already completed production of several initial batches of its “Odyssey” and “Oasis” lines of ingestible oils and will proceed with sales of these products in the medical and recreational use cannabis markets. Pre-Rolls In June this year the Company launched its “Bliss” line of pre-rolled cannabis products, which consist of blended cannabis flower, rolled in a cigarette format, or “joint”, for sale in the medical and recreational use cannabis markets. To date the Company has produced and sold over 75,000 cannabis pre-rolls. “It is management’s belief that these products will become an increasingly important component of the medical and recreational use cannabis markets in the future,” said John Arbuthnot, Chief Executive Officer of Delta 9. “A continually expanding line of high-quality cannabis products is a major goal for the Company over this year and this is the first of what we hope are several milestones in our progress.” Products for Future Development Nanosphere Evolve Products Delta 9 has acquired an exclusive license in Canada to manufacture and sell products made with the patented technology of Nanosphere Health Sciences Inc. (“NanoSphere”) for the delivery of cannabinoids via nanoparticle technology. The two companies are in the process of developing the first product for Canada; an intraoral cannabis oil containing cannabinoid nanoparticles. The NanoSphere delivery system for cannabis works by nano-encapsulating active ingredients in phospholipid membranes for transportation through the skin and mucosa into the bloodstream within minutes. Cannabis applications of the technology include transdermal viscous gels, intranasal products and intraoral products, all of which provide rapid results, precise dosages and high bioavailability. The NanoSphere delivery system of cannabis can eliminate the need for inhalation or ingestion of cannabis, offering users a potentially safer and more effective method of consumption. Dried Sift Cannabis The Company is currently developing its “Sapphire” line of dried sift cannabis products for the recreational cannabis market which involves sifting the Company’s blended products and refining them, leaving more of the high potency resin glands and less of the low potency plant material. The final product is a yellow/brownish powder and has a potency that is up to triple that of the whole flower dried cannabis materials. The Company plans to release dried sift products in the recreational cannabis market in the third quarter of 2019. Management expects that retail pricing for these products will be up to $30 per gram. Oils, Extracts, and Derivative Products The Company continues to develop and expand its in-house oils production capacity and is working with partners regarding its strategy for new cannabis extracts and derivative products once the federal government finalizes its expanded extract regulations, which are expected to become effective in 2019. About Delta 9 Cannabis Inc. Delta 9 Cannabis Inc. is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. Delta 9’s shares trade on the Toronto Stock Exchange under the symbol “DN” and on the OTCQX under the symbol VRNDF.
Delta 9大麻公司很高兴地宣布,它于2019年8月30日从加拿大卫生部获得了为期三年的续期许可证。本许可证授权Delta 9从其温尼伯生产设施种植、加工和销售大麻。该公司还很高兴向投资者提供大麻油销售、大麻卷前销售和新产品开发的最新情况。 加拿大卫生部许可证更新和石油销售授权 该公司通过其子公司Delta 9 Bio-Tech Inc.已从加拿大卫生部收到其更新的大麻标准种植和标准加工许可证。公司已达到加拿大卫生部的严格规范,并顺利通过了所有检查。 “Delta 9的员工在加拿大卫生部严格监管的许可环境中努力满足要求。Delta 9的首席执行官John Arbuthnot说:“这充分说明了我们团队的专业精神,我们按照加拿大卫生部对持牌生产商的规定,保持了安全、质量和安保的高标准。” 该公司还获得了加拿大卫生部对销售大麻油产品的批准。该公司已经完成了几批“奥德赛”和“绿洲”系列食用油的初步生产,并将继续在医疗和娱乐用大麻市场销售这些产品。 预卷 今年6月,该公司推出了预卷大麻产品的“bliss”系列,该系列由混合大麻花组成,以香烟形式卷制,或“joint”,在医疗和娱乐用大麻市场销售。迄今为止,该公司已生产和销售超过75000种大麻预卷。 Delta 9公司首席执行官约翰•阿尔布什诺(John Arbuthnot)表示:“管理层相信,这些产品未来将成为医疗和娱乐用大麻市场日益重要的组成部分。”“不断扩大高品质大麻产品线是公司今年的主要目标,这是我们希望取得进展的几个里程碑中的第一个。” 未来发展的产品 纳米球进化产物 Delta 9已在加拿大获得独家许可证,可以生产和销售使用NanoSphere Health Sciences Inc.(“NanoSphere”)专利技术生产的产品,通过纳米颗粒技术交付大麻素。这两家公司正在为加拿大开发第一种产品,一种含有大麻素纳米粒的口服大麻油。 大麻的纳米球输送系统通过在磷脂膜中纳米封装活性成分,在几分钟内通过皮肤和粘膜输送到血液中。大麻技术的应用包括经皮黏性凝胶、鼻内产品和口服产品,所有这些都提供了快速的结果、精确的剂量和高生物利用度。大麻纳米球输送系统可以消除吸入或摄入大麻的需要,为用户提供一种潜在的更安全和更有效的消费方法。 干筛大麻 该公司目前正在为休闲大麻市场开发其“蓝宝石”干筛大麻产品系列,包括筛选该公司的混合产品并对其进行精炼,从而留下更多的高效树脂腺体和更少的低效植物材料。最终产品是黄色/棕色粉末,其效力是整个花干大麻材料的三倍。该公司计划在2019年第三季度在休闲大麻市场投放干筛产品。管理层预计,这些产品的零售价格将高达每克30美元。 油、提取物和衍生产品 该公司继续发展和扩大其内部油脂生产能力,并与合作伙伴合作,一旦联邦政府最终确定其扩大的大麻提取物法规(预计将于2年生效),就其新的大麻提取物和衍生产品战略展开合作。019。 关于Delta 9大麻公司 Delta 9大麻公司是一家垂直整合的大麻公司,专注于将最高质量的大麻产品推向市场。Delta 9的全资子公司Delta 9 Bio-Tech Inc.是一家获得许可的医疗和娱乐大麻生产商,在加拿大马尼托巴省温尼伯市经营着一个80000平方英尺的生产设施。Delta 9拥有并经营Delta 9大麻商店品牌下的连锁零售店。Delta 9的股票在多伦多证券交易所以“DN”符号进行交易,在OTCQX上以“VRNDF”符号进行交易。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文